Search
Ocugen Inc
OCGNAdd to Watchlist
1.510USD
+0.030+2.03%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
510.86MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.03%
5 Days
+0.67%
1 Month
+10.22%
6 Months
+9.42%
Year to Date
+11.85%
1 Year
+57.78%
Key Figures
1.510Open
1.600High
6.96MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.06%Turnover Ratio
1.480Prev. Close
1.495Low
7.35MTurnover
LossP/E Static
88.00P/B
0.00%Div Yield TTM
-118.11%ROA
2.72552wk High
0.61Volume Ratio
-54.05MNet Profit
338.32MShares
-0.2320EPS TTM
2.23Beta
-660.00%ROE
0.80052wk Low
7.09%Amplitude
100.00%Gross Margin
510.86MMarket Cap
1.73Reward/Risk
4.65%Risk Rate
TradingKey Stock Score of Ocugen Inc
Currency: USD Updated: 2026-07-02Key Insights
Ocugen Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 116 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.43.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ocugen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Ocugen Inc Highlights
StrengthsRisks
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.41M.
Undervalued
The company’s latest PE is -6.51, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 81.01M shares, increasing 0.03% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 927.54 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.79.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
11.429
Target Price
+672.20%
Upside Space
Ocugen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ocugen Inc Info
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Ticker SymbolOCGN
CompanyOcugen Inc
CEOMusunuri (Shankar)
Websitehttps://ocugen.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Ocugen Inc (OCGN)?
The current price of Ocugen Inc (OCGN) is 1.51.
What is the symbol of Ocugen Inc?
The ticker symbol of Ocugen Inc is OCGN.
What is the 52-week high of Ocugen Inc?
The 52-week high of Ocugen Inc is 2.73.
What is the 52-week low of Ocugen Inc?
The 52-week low of Ocugen Inc is 0.80.
What is the market capitalization of Ocugen Inc?
The market capitalization of Ocugen Inc is 510.86M.
Is Ocugen Inc (OCGN) currently rated as Buy, Hold, or Sell?
According to analysts, Ocugen Inc (OCGN) has an overall rating of Buy, with a price target of 11.43.
What is the Earnings Per Share (EPS TTM) of Ocugen Inc (OCGN)?
The Earnings Per Share (EPS TTM) of Ocugen Inc (OCGN) is -0.23.